Compare

Sandoz Group AG/Fr. SDZ

1D1W1M3M6MYTD1Y5YMAX

About Sandoz Group AG

Sandoz Group AG operates in the pharmaceutical industry and is primarily focused on the development, production, and marketing of generic pharmaceuticals and biosimilars. The company offers a wide range of products including antibiotics, dermatology treatments, and respiratory medicines. Sandoz initially began as an independent company and has a notable history as part of the larger Novartis group, from which it separated to re-establish its standalone position. Headquartered in Basel, Switzerland, Sandoz has a significant global presence in various key markets. The company's strategic positioning is bolstered by its extensive portfolio of generic and biosimilar medicines, allowing it to compete effectively within the cost-sensitive segments of the pharmaceutical market.
Ticker
Fr. SDZ
Sector
Health
Primary listing
XSWX
Employees
20,000
Headquarters
Basel, Switzerland

Sandoz Group AG Metrics

BasicAdvanced
CHF 35B
65.79
CHF 1.24
0.49
CHF 0.80
0.98%

What the Analysts think about Sandoz Group AG

Analyst ratings (Buy, Hold, Sell) for Sandoz Group AG stock.
Analyst projections of the future price of Sandoz Group AG stock.

Bulls say / Bears say

Biosimilars are taking a larger share of the business: they represented 34% of Q3 sales and continued to grow year on year. This gives Sandoz a stronger growth engine than its more price-exposed generics business. (Sandoz)
Sandoz raised its 2026 core EBITDA margin forecast to 23.0%–23.5%, signalling better expected profitability even as it lowered its sales outlook. The improved product mix and cost discipline could support earnings growth despite softer near-term revenue. (Sandoz)
The Bio100 plan targets mid-to-high single-digit annual sales growth through 2030 and more than a doubling of sales by 2035, with over 100 biosimilars in the portfolio by 2040. If Sandoz delivers, the strategy offers a sizeable longer-term growth runway. (Reuters)
Sandoz cut its 2026 sales-growth outlook to 5%–6% at constant currencies after Q3 results, citing short-term biosimilar supply constraints. That shows strong demand is not yet translating fully into sales and leaves less room for near-term growth. (Reuters)
Pricing remains a headwind: Sandoz expects a mid-single-digit decline in 2026, while it also reported tougher-than-expected market conditions in Germany. Continued price pressure could limit revenue growth even if volumes rise. (Sandoz)
The US generic-drug litigation settlements require substantial payments: Sandoz agreed to pay $400 million to states over seven years and $28.5 million to reseller plaintiffs. The company also said some individual opt-out claims remain unresolved, leaving further legal uncertainty. (Sandoz)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.

Sandoz Group AG Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Sandoz Group AG Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing Sandoz Group AG

AllEURUSD
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.